Stockscreener 앱 받기
5.78
1.40%
0.08
시간 외 거래:
5.78
Coya Therapeutics Inc 주식(COYA)의 최신 뉴스
Coya Therapeutics to Present at the iAccess Alpha Virtual Best Ideas Summer Conference on June 24 – 25, 2025 - Business Wire
Trading (COYA) With Integrated Risk Controls - news.stocktradersdaily.com
Coya Therapeutics (NASDAQ:COYA) Receives Buy Rating from HC Wainwright - Defense World
Coya Therapeutics (COYA) Receives Confirmed Buy Rating from HC W - GuruFocus
Coya Therapeutics (COYA) Receives Confirmed Buy Rating from HC Wainwright | COYA Stock News - GuruFocus
Coya Therapeutics (COYA) Rated Buy by Analyst with $20 Target | COYA Stock News - GuruFocus
Jane Street Group LLC Makes New $74,000 Investment in Coya Therapeutics, Inc. (NASDAQ:COYA) - Defense World
(COYA) Trading Report - news.stocktradersdaily.com
Northern Trust Corp Has $164,000 Stock Position in Coya Therapeutics, Inc. (NASDAQ:COYA) - Defense World
Coya Therapeutics secures patent for IL-2 liquid formulation By Investing.com - Investing.com South Africa
Coya Therapeutics secures patent for IL-2 liquid formulation - Investing.com
Coya Therapeutics (COYA) Secures U.S. Patent for IL-2 Liquid Formulation | COYA Stock News - GuruFocus
Coya's Exclusive Patent Win Strengthens IL-2 Drug Pipeline as Phase 2b ALS Trial Approaches - Stock Titan
(COYA) Investment Report - news.stocktradersdaily.com
Brokers Issue Forecasts for COYA Q1 Earnings - Defense World
Q3 EPS Forecast for Coya Therapeutics Increased by Analyst - Defense World
Coya Therapeutics Reports First Quarter Financial Results and Provides a Corporate Update - Business Wire
Coya Therapeutics: Promising Developments and Strategic Partnerships Drive Buy Rating - TipRanks
Coya Therapeutics First Quarter 2025 Earnings: Misses Expectations - Yahoo Finance
FY2026 Earnings Forecast for COYA Issued By Chardan Capital - Defense World
Coya Therapeutics to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor Conference - Business Wire
Coya Therapeutics, Inc. (NASDAQ:COYA) Stock Holdings Lifted by Tower Research Capital LLC TRC - Defense World
Coya Therapeutics (COYA): Analyst Maintains Buy Rating and Price - GuruFocus
Critical Survey: Coya Therapeutics (NASDAQ:COYA) vs. BioVie (NASDAQ:BIVI) - Defense World
Coya Therapeutics Reports Q1 2025 Financial Results - TipRanks
Coya (COYA) Reports Lower Q1 Revenue Than Expected | COYA Stock News - GuruFocus
Coya Therapeutics (COYA) Reports Q1 EPS and Cash Position - GuruFocus
Coya Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Coya Therapeutics to Participate in Two Upcoming Conferences in May 2025 - Stock Titan
Coya Therapeutics (COYA) Projected to Post Quarterly Earnings on Thursday - Defense World
How To Trade (COYA) - news.stocktradersdaily.com
Coya Therapeutics, Inc. (NASDAQ:COYA) Shares Acquired by Geode Capital Management LLC - Defense World
Coya Therapeutics advances COYA 303 for inflammatory diseases - MSN
Is Coya Therapeutics, Inc. (COYA) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Coya Therapeutics’ (COYA) “Buy” Rating Reaffirmed at Chardan Capital - Defense World
Biotech Company Reports Promising Neurological Treatment in Clinical Study - streetwisereports.com
Coya Therapeutics: Treg Proof-Of-Concept Continues With Interim FTD Data Release - Seeking Alpha
Coya Therapeutics Announce Positive Interim Result from - openPR.com
Coya Therapeutics Announces Positive Interim Results of an Investigator-Initiated Open Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Five Patients with Mild to Moderate Frontotemporal Dementia – EventsNewsAsia.com - eventsnewsasia.com
Biotech Discovers Revolutionary Immunotherapy in Houston - streetwisereports.com
Coya stock in focus after interim results for dementia drug - Seeking Alpha
Coya Reports Positive Data From Proof Of Concept Open-label Study Of IL-2 And CTLA4-Ig Combo In FTD - Nasdaq
Coya Therapeutics Announces Positive Interim Results of an Investigator-Initiated Open Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Five Patients with Mild to Moderate Frontotemporal Dementia - businessnews.ph
Coya Therapeutics Announces Positive Interim Results Of An Investigator-Initiated Open Label Study With Low-Dose IL-2 And CTLA4-Ig Combination Treatment In Five Patients With Mild To Moderate Frontotemporal Dementia - marketscreener.com
Revolutionary Frontotemporal Dementia Treatment Prevents Cognitive Decline in All Trial Patients - Stock Titan
Coya Therapeutics (NASDAQ:COYA) Earns Buy Rating from D. Boral Capital - Defense World
Wall Street Analysts See a 144.73% Upside in Coya Therapeutics, Inc. (COYA): Can the Stock Really Move This High? - Yahoo Finance
AI in Clinical Trials Market Growth 2025: Trends, Consumer - openPR.com
Coya Therapeutics (NASDAQ:COYA) Trading 8.6% Higher – What’s Next? - Defense World
Coya Therapeutics, Inc. Announces Publication of GLP-1/LD IL-2 Combination Biologic (COYA 303) Demonstrating Synergistic Enhancement of Regulatory T Cell Function and Protection Against Treg Apoptosis (Cell Death) - marketscreener.com
1.45%
0.86%
자본화:
|
볼륨(24시간):